Degradation of TRIM32 is induced by RTA for Kaposi’s sarcoma-associated herpesvirus lytic replication
Journal of Virology · 2024
DOI: 10.1128/jvi.00005-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Yulin Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Cente…. Hauptthemen laut MEDLINE: Herpesvirus 8, Human, Immediate-Early Proteins, Proteolysis, Trans-Activators. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), MOST | National Key Research and Development Program of China.
Abstract (Originalsprache)
TRIM32 is often aberrantly expressed in many types of cancers. Kaposi’s sarcoma-associated herpesvirus (KSHV) is linked with several human malignancies, including Kaposi’s sarcoma and primary effusion lymphomas (PELs). Increasing evidence has demonstrated the crucial role of KSHV lytic replication in viral tumorigenesis. However, the role of TRIM32 in herpesvirus lytic replication remains unclear. Here, we reveal that the expression of TRIM32 is upregulated by KSHV in latency, and reactivation of KSHV lytic replication leads to the inhibition of TRIM32 in PEL cells. Strikingly, RTA, the master regulator of lytic replication, interacts with TRIM32 and dramatically promotes TRIM32 for degradation via the proteasome systems. Inhibition of TRIM32 induces cell apoptosis and in turn inhibits the proliferation and colony formation of KSHV-infected PEL cells and facilitates the reactivation of KSHV lytic replication and virion production. Thus, our data imply that the degradation of TRIM32 is vital for the lytic activation of KSHV and is a potential therapeutic target for KSHV-associated cancers. IMPORTANCE TRIM32 is associated with many cancers and viral infections; however, the role of TRIM32 in viral oncogenesis remains largely unknown. In this study, we found that the expression of TRIM32 is elevated by Kaposi’s sarcoma-associated herpesvirus (KSHV) in latency, and RTA (the master regulator of lytic replication) induces TRIM32 for proteasome degradation upon viral lytic reactivation. This finding provides a potential therapeutic target for KSHV-associated cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganism and Infection, School of Basic Medical S…
- ShengYushou Center of Cell Biology and Immunology, Joint International Research Laboratory of Metabolic & Development Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Yuyan Wang, Fang Wei, Qiliang Cai
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- MOST | National Key Research and Development Program of China
Zitieren
APA
Zhang, Y., Dong, Z., Gu, F., Xu, Y., Li, Y., Sun, W., Rao, W., Du, S., Zhu, C., Wang, Y., Wei, F., & Cai, Q. (2024). Degradation of TRIM32 is induced by RTA for Kaposi’s sarcoma-associated herpesvirus lytic replication. Journal of Virology. https://doi.org/10.1128/jvi.00005-24
Vancouver
Zhang Y, Dong Z, Gu F, Xu Y, Li Y, Sun W, et al. Degradation of TRIM32 is induced by RTA for Kaposi’s sarcoma-associated herpesvirus lytic replication. Journal of Virology. 2024. doi:10.1128/jvi.00005-24
BibTeX
@article{Zhang2024,
author = {Zhang, Yulin and Dong, Zhongwei and Gu, Feng and Xu, Yifei and Li, Ying and Sun, Wen and Rao, Wutian and Du, Shujuan and Zhu, Caixia and Wang, Yuyan and Wei, Fang and Cai, Qiliang},
title = {Degradation of TRIM32 is induced by RTA for Kaposi’s sarcoma-associated herpesvirus lytic replication},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.00005-24}
}
EUVIMED